The phase 2 PHAROS study previously showed that encorafenib plus binimetinib has antitumor activity in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (mNSCLC). In PHAROS, 98 ...
BERLIN October 17, 2025 – Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival ...
Forever ensnared in a love-fued between 1800s literature and modern gaming, Eman Fatima tries her best to appease both her hobbies by tapping away at her keyboard and writing about her favorite games ...
In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival. Clinical trial results have shown that among patients with locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback